Later this month nearly 16,000 attendees and roughly 2,000 ex- hibitors presenting exciting innovations in biotechnology will descend on San Diego for BIO 2017. The largest event of its
kind, the Bio International Convention will take place June 20-22,
and offer access to the latest bio industry trends from development
to manufacturing to regulations and everything in between.
In the lead up to BIO 2017, the final landing destination for
the June issue of Contract Pharma, we’ve gathered some bio-fo-cused content for you before heading off to Cali, if you are going,
that is. If not, it still makes for good reading.
We called on Contract Pharma editorial advisory board member
William Downey, president of High Tech Business Decisions, to talk
about the latest trends in the biopharma contract manufacturing
market, which he predicts will grow to exceed $4 billion this year, all
the while experiencing double-digit growth over the past three years
as new biopharmaceuticals reached the market or entered the pipeline. Beginning on page 38, he says high demand plus low capacity
expansion rates caused high industry utilization rates last year and
as a result biopharma CMOs are aggressively adding capacity and
investing in productivity improving technologies.
Contract Pharma’s resident BioPharm Insider, Eric Langer,
president of BioPlan Associates, looks at budget increases in the
biopharmaceutical industry as an indication of future growth.
Starting on page 30, he says by examining whether biomanufacturers and CMOs are planning to increase or decrease spending in critical areas gives a good indication of the current health
of the industry and the projected growth, or contraction, expected
in the future.
Based on his firms“14th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production,” which
surveyed 227 biomanufacturers and CMOs about their budget
and planned expenditures, he looks at not only general increases
or decreases, but also, over the past eight years, the specific areas
those in the industry are planning budget shifts.
Lastly on the bio front, we interviewed Joanne Anderson, business development director for the Scottish CMO, Symbiosis Pharmaceutical Services, which just this year opened up shop in the U.S.
with a facility in the Boston area. Beginning on page 46, we discuss
trends in the current biologics fill/finish market. She says while the
market will always be subject to change, the company believes there
is significant market demand for aseptic manufacturing capabilities
for biologics that has been boosted by a positive investment climate
in the biotech space, particularly in the U.S.
If you are going to be in San Diego later this month, Contract
Pharma will be at booth 1630 if you want to stop by and say hi.
Hope to see you there!
Tim Wright, Editor
Heading to BIO 2017!
Biotechs top people and newest technology innovations will be on hand in San Diego later this month.